全文获取类型
收费全文 | 10937篇 |
免费 | 734篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 123篇 |
儿科学 | 277篇 |
妇产科学 | 171篇 |
基础医学 | 1465篇 |
口腔科学 | 358篇 |
临床医学 | 1479篇 |
内科学 | 1848篇 |
皮肤病学 | 91篇 |
神经病学 | 959篇 |
特种医学 | 445篇 |
外科学 | 1096篇 |
综合类 | 182篇 |
一般理论 | 8篇 |
预防医学 | 1271篇 |
眼科学 | 312篇 |
药学 | 798篇 |
中国医学 | 11篇 |
肿瘤学 | 836篇 |
出版年
2023年 | 37篇 |
2022年 | 41篇 |
2021年 | 114篇 |
2020年 | 99篇 |
2019年 | 171篇 |
2018年 | 157篇 |
2017年 | 139篇 |
2016年 | 170篇 |
2015年 | 208篇 |
2014年 | 257篇 |
2013年 | 455篇 |
2012年 | 650篇 |
2011年 | 762篇 |
2010年 | 382篇 |
2009年 | 382篇 |
2008年 | 667篇 |
2007年 | 752篇 |
2006年 | 768篇 |
2005年 | 771篇 |
2004年 | 680篇 |
2003年 | 644篇 |
2002年 | 673篇 |
2001年 | 155篇 |
2000年 | 111篇 |
1999年 | 137篇 |
1998年 | 152篇 |
1997年 | 155篇 |
1996年 | 117篇 |
1995年 | 106篇 |
1994年 | 89篇 |
1993年 | 109篇 |
1992年 | 91篇 |
1991年 | 116篇 |
1990年 | 89篇 |
1989年 | 104篇 |
1988年 | 88篇 |
1987年 | 76篇 |
1986年 | 70篇 |
1985年 | 77篇 |
1984年 | 77篇 |
1983年 | 84篇 |
1982年 | 82篇 |
1981年 | 84篇 |
1980年 | 67篇 |
1979年 | 57篇 |
1978年 | 37篇 |
1977年 | 48篇 |
1976年 | 48篇 |
1974年 | 39篇 |
1972年 | 36篇 |
排序方式: 共有10000条查询结果,搜索用时 156 毫秒
1.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
2.
3.
4.
5.
Abdominal Radiology - 相似文献
6.
7.
Methylene Blue Absorption in Sentinel Lymph Node Biopsy for Early Breast Cancer after Neoadjuvant Chemotherapy 下载免费PDF全文
Terry SoebhiKristanto Yuli YarsoFarida SobriIda Bagus Budhi 《Asian Pacific journal of cancer prevention》2020,21(6):1767-1771
Introduction: Chemotherapy is claimed to cause lymphatic drainage damage because of the tumor cell’s apoptosis process. This event might cause decreased marker (radioactive solution and/or blue dye) absorption on sentinel lymph nodes (SLN). In this study, the researchers used methylene blue only and wished to evaluate the methylene blue absorption of the SLNB procedure on early-stage breast-cancer patients after neoadjuvant chemotherapy (NAC). Materials and methods: The method used was the historical cohort study conducted from 2016-2019 in Indonesia. Samples were collected from 117 patients of stage I and II breast cancer with clinically negative axillary lymph nodes, who were then grouped into post-NAC and no-NAC (control group), in which SLNB procedures were conducted on the two groups by using single-method methylene blue. The results of methylene blue absorption were then analyzed by the Chi-square hypothesis test. Results: From the total of 564 early-stage patients who were referred to surgical oncologists, 117 patients were found to meet criteria of inclusion, consisting of the control group (52 patients) and the post-NAC group (65 patents). Of 65 patients who had undergone NAC treatment and SLNB procedure, it was found that 40 patients (61.5%) showed positive blue SLN. Of 52 pre-NAC breast-cancer patients, it was found that 47 patients (90.4%) showed methylene blue absorption on SLN with the p-value of 0.000 (P<0.05, significant). The relative risk value amounted to 0.522. Post-NAC patients had a tendency of decreased absorption of methylene blue. Conclusion: Neoadjuvant chemotherapy can cause the decrease of methylene blue absorption on SLNB procedure. 相似文献
8.
Phantana-angkool April Voci Amy E. Warren Yancey E. Livasy Chad A. Beasley Lakesha M. Robinson Myra M. Hadzikadic-Gusic Lejla Sarantou Terry Forster Meghan R. Sarma Deba White Richard L. 《Annals of surgical oncology》2019,26(12):3874-3882
Annals of Surgical Oncology - The role of sentinel lymph node biopsy (SLNB) when ductal carcinoma in situ with microinvasion (DCISM) is identified on core biopsy is unclear. Our aim was to assess... 相似文献
9.
10.